written on 06.05.2014

Allergan deal-backer Ackman orders board to start talking to Valeant


Rumor has it Allergan is scouting about for acquisition targets and white knights to help it dodge an unwanted Valeant Pharmaceuticals takeover. But activist investor Bill Ackman, who has teamed with the Canadian pharma on the pickup bid, doesn't necessarily think that's a good idea.